Dissemination Materials Sample Clauses

Dissemination Materials. In this section, we describe the dissemination materials that were produced and/or harnessed in the first half of the project. The strategy shows a wide-reaching approach to peer reviewed publications that target Academia, Industry, and the Clinic, while popularised publications target the General Public in addition to those same groups. Our video content has gained attention, with a fast building YouTube following keen on our content such as recorded talks/webinars, as well as our continuing dissemination campaign surrounding the Virtual Humans film produced in CompBioMed1. Meanwhile, our newsletters, posters, and other materials have kept a steady flow of dissemination into the world throughout the first 25 months of the project.
Sample 1Sample 2
AutoNDA by SimpleDocs
Dissemination Materials. Development of materials for use in national follow-up presentations of project progress and results. Deliverables Deliverable D1: Project internal Internet home page Date due: Month 3 Deliverable D3: Brochure presenting the project Date due: Month 6 Starting date: Month No. 1 Duration: 36 months Total Effort: 18 Deliverable D32: Executive summary report of the project Date due: Month 36 Deliverable D33: Follow-up materials to support project progress and results Date due: Month 36 Milestones and criteria Milestone M17: Mid-term follow-up. Date due: Month 19 Consistency demonstrated with work programme and objectives. Milestone M19: Final symposium. Date due: Month 33 Preparations for the final symposium completed. Interrelation with other work packages WP 16 will work towards dissemination, implementation and exploitation of the outputs of WP 2, WP 3, WP 4,WP 5, WP 12, WP 13, WP 14 and WP 15. It will also integrate the technical outputs of these WPs into the Executive summary report.
Sample 1
Dissemination Materials. In addition to the two (2) sets of leaflets and posters committed in the DoW, additional printing materials may be designed on demand at any time, tailored to the event and target audience where they will be used. A new brochure is also expected to be released when milestone MS2.3 is reached (Successful availability of the infrastructure of the FIBRE-BR facilities). This material will be aimed at attracting outside researchers and students to use the facilities to run their experiments. To ensure continuous coverage of project activities, press releases will be produced before and after any FIBRE event. Their respective files will also be available in electronic format on the project web site1. Depending on the targeted audience and the venue where the project will be disseminated, some materials might be produced in Portuguese only. This dissemination plan also expects FIBRE members to attend major related events in the next years, preferably presenting FIBRE outcomes in talks, posters and/or technological demonstrations. The series of events most likely to FIBRE members to attend are:  Brazilian Symposium on Computer Networks and Distributed Systems (SBRC)  Brazilian Symposium on Telecommunications (SBrT 2012)  European Workshop on Software Defined Networks (EWSDN)  Future Internet Assembly  GENI Engineering Conference (GEC)  Open Network Summit  RNP Workshop (WRNP)  XXXXXX Networking Conference (TNC)  TridentCom At the time of writing this deliverable, not all events, dates and locations were defined for 2013 and 2014.
Sample 1
Dissemination Materials. Figure 18 Documents library Dissemination materials
Sample 1
Dissemination Materials. In this section, we describe the dissemination materials that were produced and/or harnessed in the second half of the project. The strategy shows a wide-reaching approach to peer reviewed publications that targets Academia, Industry and the Clinic, while popularised publications target the general public in addition to those same groups. Our video content gains attention thanks to a high number of recorded talks, as well as our major dissemination campaign surrounding the Virtual Humans film. Meanwhile, our newsletters, posters, and other materials have kept a steady flow of dissemination into the world throughout the second half of the project.
Sample 1
Dissemination Materials. In terms of printed materials for dissemination and networking, the following documents and print templates were identified, and some of them already designed during the first months of the project: 1. General-purpose A4 factsheet, front/back printed, to be deployed at various events as a general presentation of the project.
Sample 1
Dissemination Materials 
Sample 1
AutoNDA by SimpleDocs

Related to Dissemination Materials

  • Solicitation Materials Neither the Company nor any Person acting on the Company's behalf has solicited any offer to buy or sell the Securities by means of any form of general solicitation or advertising.

  • Dissemination 1. All public events, activities, curricular materials, press releases, requests for proposals, bid solicitations, and other documents produced with OSHE funds provided pursuant to this agreement must state clearly that the project partnership is administered by OSHE and that OSHE is a partner in the project partnership. The only official name to be used in describing the overall program is “Educational Opportunity Fund (EOF)” and no other institutional- specific branded name shall be used in official communication about the grants.

  • Customer Materials Subject to Section 4(a), all right, title and interest (including all Intellectual Property Rights) in and to the Customer Materials are owned by Customer or Customer’s suppliers.

  • Proxy Materials The Custodian shall deliver, or cause to be delivered, to the Fund proxy forms, notices of meeting, and any other notices or announcements materially affecting or relating to Investments received by the Custodian or any nominee.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • User Information Any user or usage data or information collected via Station’s digital properties or related to Station’s digital properties, or any information collected from websites operated by Station’s affiliates under this Agreement, shall be the property of Station and/or such affiliates. Advertiser shall have no rights in such information by virtue of this Agreement.

  • Patient Information Each Party agrees to abide by all laws, rules, regulations, and orders of all applicable supranational, national, federal, state, provincial, and local governmental entities concerning the confidentiality or protection of patient identifiable information and/or patients’ protected health information, as defined by any other applicable legislation in the course of their performance under this Agreement.

  • Company Information Subscriber understands that the Company is subject to all the risks that apply to early-stage companies, whether or not those risks are explicitly set out in the Offering Circular. Subscriber has had such opportunity as it deems necessary (which opportunity may have presented through online chat or commentary functions) to discuss the Company’s business, management and financial affairs with managers, officers and management of the Company and has had the opportunity to review the Company’s operations and facilities. Subscriber has also had the opportunity to ask questions of and receive answers from the Company and its management regarding the terms and conditions of this investment. Subscriber acknowledges that except as set forth herein, no representations or warranties have been made to Subscriber, or to Subscriber’s advisors or representative, by the Company or others with respect to the business or prospects of the Company or its financial condition.

  • Client Information Protected Health Information in any form including without limitation, Electronic Protected Health Information or Unsecured Protected Health Information (herein “PHI”);

  • Regulatory Information (a) All the notaries at De Pinna LLP are regulated through the Faculty Office of the Archbishop of Canterbury. Its address is The Faculty Office, 0 Xxx Xxxxxxxxx, Xxxxxxxxxxx, Xxxxxx XX0X 0XX, its telephone: 000 0000 0000, and it can be reached by email at xxxxxxx.xxxxxx@0xxxxxxxxxxxx.xxx. It also has a website at xxx.xxxxxxxxxxxxx.xxx.xx. (b) We are required to comply with the rules of professional conduct and other regulatory arrangements of the Master of the Faculties, the sole regulator of notarial activities under the Legal Services Act 2007. Information about those rules and regulations may be found at xxxx://xxx.xxxxxxxxxxxxx.xxx.xx/notary/i-am-a-notary/notaries-rules-regulations/. (c) We comply with the Code of Practice published by the Master of the Faculties: xxxx://xxx.xxxxxxxxxxxxx.xxx.xx/notary/code-of-practice.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!